Table 2.
Clinical features of the patients with HBV-related HCC.
| Variable | Patients (n=419)(%) |
MST (months) |
Log-rank P | HR(95% CI) |
|---|---|---|---|---|
| Gender | ||||
| Male | 377 | 51 | 0.277 | 1 |
| Female | 42 | 80 | 0.749(0.442-1.268) | |
| Age(year) | ||||
| ≤46 | 229 | 61 | 0.974 | 1 |
| >46 | 190 | 51 | 1.005(0.758-1.331) | |
| Race | ||||
| Han | 261 | 51 | 0.875 | 1 |
| Minority | 158 | 52 | 1.023(0.764-1.371) | |
| Smoking status | ||||
| No | 270 | 71 | 0.106 | 1 |
| Yes | 149 | 41 | 1.267(0.949-1.692) | |
| Drinking status | ||||
| No | 250 | 76 | 0.043 | 1 |
| Yes | 169 | 41 | 1.335(1.006-1.770) | |
| BMI | ||||
| ≤25 | 348 | 52 | 0.918 | 1 |
| >25 | 71 | 51 | 0.981(0.683-1.410) | |
| AFP(ng/ml)a | ||||
| ≤400 | 214 | 63 | 0.114 | 1 |
| >400 | 175 | 42 | 1.265(0.943-1.697) | |
| Child-pughb | ||||
| A | 337 | 58 | 0.181 | 1 |
| B | 56 | 34 | 1.291(0.877-1.900) | |
| BCLC stage | ||||
| A | 239 | 123 | <0.001 | 1 |
| B | 69 | 95 | 1.880(1.281-2.758) | |
| C | 111 | 29 | 2.766(2.021-3.786) | |
| No. of tumors | ||||
| Single(n=1) | 308 | 63 | 0.001 | 1 |
| Multiple(n>1) | 111 | 34 | 1.642(1.219-2.212) | |
| Tumor size | ||||
| ≤5cm | 138 | 123 | <0.001 | 1 |
| >5cm | 281 | 40 | 1.981(1.416-2.770) | |
| Cirrhosis | ||||
| No | 50 | 88 | 0.191 | 1 |
| Yes | 369 | 51 | 1.358(0.854-2.158) | |
| Pathological gradec | ||||
| Well | 24 | 79 | 0.473 | 1 |
| Moderately/Poorly | 340 | 51 | 1.276(0.651-2.499) | |
| PVTT | ||||
| No | 352 | 47 | <0.001 | 1 |
| Yes | 67 | 40 | 2.801(2.025-3.875) | |
| Radical resectiond | ||||
| No | 169 | 41 | 0.115 | 1 |
| Yes | 238 | 73 | 1.254(0.944-1.667) | |
| Antiviral therapy | ||||
| No | 276 | 42 | 0.020 | 1 |
| Yes | 143 | NA | 0.675(0.483-0.945) | |
Notes: a information regarding AFP level was unavailable for 30 patients; b information regarding child-pugh was unavailable for 26 patients; c information regarding pathological grade was unavailable for 55 patients; d information regarding radical resection was unavailable for 12 patients. HBV, hepatitis B virus; HCC, hepatocellular carcinoma; BMI, body mass index; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; MST, median survival time; HR, hazard ratio; CI, confidence interval; NA, not available.